Decoy Therapeutics, Inc. (DCOY)
3.03
-0.03
(-0.98%)
USD |
NASDAQ |
Sep 02, 16:00
3.03
0.00 (0.00%)
After-Hours: 16:47
Decoy Therapeutics Free Cash Flow : -8.367M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.367M |
| March 31, 2026 | -6.535M |
| December 31, 2025 | -4.827M |
| September 30, 2025 | -4.433M |
| June 30, 2025 | -4.143M |
| March 31, 2025 | -4.353M |
| December 31, 2024 | -4.525M |
| September 30, 2024 | -5.294M |
| June 30, 2024 | -7.686M |
| March 31, 2024 | -11.03M |
| December 31, 2023 | -12.85M |
| September 30, 2023 | -16.05M |
| June 30, 2023 | -18.04M |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| December 31, 2021 | -10.20M |
| September 30, 2021 | -8.856M |
| June 30, 2021 | -10.03M |
| March 31, 2021 | -9.329M |
| December 31, 2020 | -10.31M |
| Date | Value |
|---|---|
| September 30, 2020 | -11.57M |
| June 30, 2020 | -14.36M |
| March 31, 2020 | -13.42M |
| December 31, 2019 | -11.58M |
| September 30, 2019 | -8.556M |
| June 30, 2019 | 18.44M |
| March 31, 2019 | 11.72M |
| December 31, 2018 | 4.177M |
| September 30, 2018 | -1.981M |
| June 30, 2018 | -31.53M |
| March 31, 2018 | -29.00M |
| December 31, 2017 | -27.84M |
| September 30, 2017 | -28.41M |
| June 30, 2017 | -27.79M |
| March 31, 2017 | -31.58M |
| December 31, 2016 | -32.61M |
| September 30, 2016 | -31.74M |
| June 30, 2016 | -31.12M |
| March 31, 2016 | -26.13M |
| December 31, 2015 | -21.01M |
| September 30, 2015 | -19.44M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Palatin Technologies, Inc. | -14.98M |
| Unicycive Therapeutics, Inc. | -27.85M |
| Nuvectis Pharma, Inc. | -19.51M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.652M |
| Cash from Investing (Quarterly) | -0.0424M |
| Cash from Financing (Quarterly) | 3.163M |
| Free Cash Flow Per Share (Quarterly) | -5.065 |
| Free Cash Flow to Equity (Quarterly) | -2.694M |
| Free Cash Flow to Firm (Quarterly) | -2.694M |
| Free Cash Flow Yield | -675.1% |